XTX Topco Ltd Sells 7,494 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

XTX Topco Ltd cut its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 45.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,997 shares of the company’s stock after selling 7,494 shares during the period. XTX Topco Ltd’s holdings in SpringWorks Therapeutics were worth $288,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its holdings in SpringWorks Therapeutics by 47.9% in the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock valued at $45,000 after acquiring an additional 383 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in SpringWorks Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock valued at $87,000 after acquiring an additional 474 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in SpringWorks Therapeutics in the second quarter valued at approximately $123,000. Quantbot Technologies LP bought a new stake in SpringWorks Therapeutics in the third quarter valued at approximately $147,000. Finally, Quarry LP boosted its holdings in SpringWorks Therapeutics by 56.3% in the second quarter. Quarry LP now owns 5,000 shares of the company’s stock valued at $188,000 after acquiring an additional 1,800 shares during the last quarter.

SpringWorks Therapeutics Stock Performance

Shares of SWTX opened at $37.72 on Wednesday. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $53.92. The business’s 50 day moving average price is $35.14 and its two-hundred day moving average price is $36.49. The firm has a market cap of $2.81 billion, a PE ratio of -9.72 and a beta of 0.86.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The company had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. During the same period in the prior year, the firm earned ($1.27) earnings per share. SpringWorks Therapeutics’s revenue for the quarter was up 4810.0% on a year-over-year basis. Research analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 EPS for the current fiscal year.

Insider Transactions at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the transaction, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at $8,796,912. This represents a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.61% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on SWTX. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a report on Monday, November 18th. Evercore ISI started coverage on SpringWorks Therapeutics in a research note on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target on the stock. HC Wainwright dropped their price target on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. boosted their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics currently has a consensus rating of “Buy” and an average price target of $69.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.